New anticancer agents and therapeutic strategies in development for solid cancers: A clinical perspective

Expert Review of Anticancer Therapy

Volumn 4, Issue 1, 2004, Pages 53-60

  Awada, Ahmad ^a   Mano, Max ^a   Hendlisz, Alain ^a   Piccart, Martine ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Biological target; Drug development; Molecular targeted therapy; New chemotherapeutic agents; Solid tumors

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BMS 184476; BORTEZOMIB; CYTOTOXIC AGENT; EPOTHILONE B; EPOTHILONE DERIVATIVE; IXABEPILONE; LONAFARNIB; MONOCLONAL ANTIBODY; PACLITAXEL DERIVATIVE; PACLITAXEL POLIGLUMEX; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; RAF PROTEIN; RPR 109881A; RPR 116258A; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY; VATALANIB; VINFLUMINE;

ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE; CLINICAL TRIAL; DIARRHEA; DRUG TARGETING; EDEMA; FATIGUE; GASTROINTESTINAL DISEASE; HAIR DISEASE; HAND FOOT SYNDROME; HUMAN; MONOTHERAPY; MUCOSA INFLAMMATION; NEUROPATHY; NEUTROPENIA; PROTEIN BINDING; SENSORY NEUROPATHY; SKIN DISCOLORATION; SKIN TOXICITY; SOLID TUMOR; THROMBOCYTOPENIA;

EID: 1142291736     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.1.53     Document Type: Article

References (20)

1. Awada A. New cytotoxic agents and molecular-targeted therapies in the treatment of metastatic breast cancer. Forum (Genova) 12(1), 4-18 (2002).
2. Awada A, Cardoso F, Atalay G, Giuliani R, Mano M, Piccart MJ. The pipeline of new anticancer agents for breast cancer treatment in 2003. Crit. Rev. Oncol. Hematol. 48(1), 45-63 (2003).
3. Roche HH, Cure H, Bunnell C et al. A Phase II study of epothilone analog BMS-247550 in patients with metastatic breast cancer previously treated with an anthracycline. Proc. Am. Soc. Clin. Oncol. 22 (2003) (Abstract 69).
4. Thomas E, Tabernero J, Fornier M et al. A Phase II study of the epothilone B analog BMS-247550 in patients with taxane-resistant metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 22 (2003) (Abstract 30).
5. Van Oosterom AT, Dumez H, Calvert AH et al. Phase I dose-escalation trial evaluating the safety and tolerability of EPO906 plus capecitabine in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. 22 (2003) (Abstract 624).
6. Awada A, Eskens FA, Piccart M et al. Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH-66336 given once daily to patients with advanced solid tumors. Eur. J. Cancer 38(17), 2272-2278, (2002).
7. Eskens FA, Awada A, Cutler DL et al. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J. Clin. Oncol. 19(4), 1167-1175 (2001).
8. Zujewski J, Horak ID, Bol CJ et al. Phase I and pharmacokinetic study of farnesyltransferase inhibitor R115777 in advanced cancer. J. Clin. Oncol. 18(4), 927-941 (2000).
9. Piccart-Gebhart MJ, Branle F, de Valeriola D et al. A Phase I, clinical and pharmacokinetic (PK) trial of the farnesyl transferase inhibitor (FTI) R115777 plus docetaxel: a promising combination in patients (pts) with solid tumors. Proc. Am. Soc. Clin. Oncol. (2001) (Abstract 318).
10. Strumberg D, Awada A, Piccart M. Final report of the Phase I clinical program of the novel raf kinase inhibitor BAY 43-9006 in patients with refractory solid tumors. Proc. Am. Soc. Clin. Oncol. 22 (2003) (Abstract 813).
11. Awada A, Hendlisz H, Gil T et al. Final results of a clinical and pharmacokinetic (PK) Phase I study of the Raf kinase inhibitor BAY 43-9006 in refractory solid cancers: a promising antitumor agent. Eur. J. Cancer 38(Suppl. 7), S52 (2002) (Abstract 162).
12. Hirte H, Moore M, Hotte S. Final results of a Phase I study of the Raf-1 kinase inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. Eur. J. Cancer 38 (Suppl. 7), S55 (2002) (Abstract 173).
13. Siu L, Awada A, Takimoto CH et al. Phase I study of oral raf-1 kinase inhibitor BAY 43-9006 with gemcitabine in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 22 (2003) (Abstract 828).
14. Mitchell BS. The proteasome - an emerging therapeutic target in cancer. N. Engl. J. Med. 348(26), 2597-2598, (2003).
15. Richardson PG, Barlogie B, Berenson J et al. A Phase II study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348(26), 2609-2617 (2003).
16. Albanell J, Baselga J, Guix M et al. Phase I study of bortezomib in combination with docetaxel in anthracycline-pretreated advanced breast cancer. Proc. Am. Soc. Clin. Oncol. 22 (2003) (Abstract 63).
17. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody for metastatic renal cancer. N. Engl. J. Med. 49, 427-434, (2003).
18. Miller K, Rugo H, Cobleigh M et al. Phase III trial of capecitabine (Xeloda®) plus bevacizumab (Avastin™) versus capecitabine alone in women with metastatic breast cancer previously treated with an anthracycline and a taxane. Breast Cancer Res. Treat. 76(Suppl. 1), S37 (2002) (Abstract 36).
19. Raymond E, Faivre S, Vera K. First results of a Phase I and pharmacokinetic study of SU011248, a novel oral anti-angiogenic agent, in patients with advanced solid tumors. Eur. J. Cancer 38(Suppl. 7), S17 (Abstract 39) (2002).
20. George D, Michaelson D, Oh WK et al. Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 22 (2003) (Abstract 1548).